期刊文献+

新型冠状病毒病(COVID-19)并发心肌损伤的研究现状 被引量:2

Research status of COVID-19 complicated with acute myocardial injury
下载PDF
导出
摘要 新型冠状病毒病(coronavirus disease 2019,COVID-19)是由急性呼吸综合征新型冠状病毒(SARS-CoV-2)引起的一种感染性极强的严重呼吸系统综合征,目前已形成世界性大爆发,给人类健康和全球经济带来了极大的影响。现有研究表明,COVID-19除了影响呼吸系统外,还对心血管系统有侵害作用,引起心肌损伤,预后较差。本文就现有的COVID-19并发心肌损伤的病原学、潜在的发病机制、相关临床表现特征、治疗原则及预后等方面研究进行论述,旨在加深临床医师对COVID-19并发心肌损伤的认识。 The coronavirus disease(COVID-19)is a highly infectious severe respiratory system syndrome caused by acute respiratory syndrome virus(SARS-COV-2),which has now a worldwide outbreak and has a huge impact on human health and the global economy.In addition to respiratory system infection,COVID-19 has been shown to have an adverse effect on the cardiovascular system,leading to myocardial damage and poor prognosis.This article reviews the current studies on the etiology,potential pathogenesis,clinical features,treatment principles and prognosis of COVID-9 associated with myocardial injury,so as to deepen the clinical understanding of COVID-19 patients with myocardial injury.
作者 姜超 罗东雷 郭靖涛 舒红军 JIANG Chao;LUO Dong-lei;GUO Jing-tao;SHU Hong-jun(Graduate School,Chengde Medical University;Department of Cardiology,Chengde Central Hospital/Second Clinical College of Chengde Medical University,Chengde 067000,Hebei,China)
出处 《心脏杂志》 CAS 2020年第4期434-439,共6页 Chinese Heart Journal
关键词 新型冠状病毒病 心肌损伤 临床表现 实验室检查 治疗 coronavirus disease 2019(COVID-19) myocardial injury clinical manifestations laboratory tests treatment
  • 相关文献

参考文献11

二级参考文献37

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652. 被引量:1
  • 3Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867. 被引量:1
  • 4Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868. 被引量:1
  • 5Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293. 被引量:1
  • 6Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719. 被引量:1
  • 7Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S. 被引量:1
  • 8Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S. 被引量:1
  • 9Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11 : 493 -496. 被引量:1
  • 10Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med, 2011,155:653-659. 被引量:1

共引文献5075

同被引文献16

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部